CD44 and neoplasm: Thus, PS-LY/CpG may be agood candidate for liver cancer and other tumor therapies.126 The NPs were functionalized with CGKRK peptideto achieve targeted biodistribution in tumor sites through overexpressionvia heparan sulfate proteoglycan binding in the TME.